Zolmitriptan 5mg orodispersible tablets sugar free

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Zolmitriptan

Available from:

Arrow Generics Ltd

ATC code:

N02CC03

INN (International Name):

Zolmitriptan

Dosage:

5mg

Pharmaceutical form:

Orodispersible tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04070401; GTIN: 5060034835028

Patient Information leaflet

_PACKAGE LEAFLET: INFORMATION FOR THE USER_
_ZOLMITRIPTAN 2.5 MG ORODISPERSIBLE TABLETS_
_ZOLMITRIPTAN 5 MG ORODISPERSIBLE TABLETS_
Zolmitriptan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING
THIS MEDICINE.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or
pharmacist.
• This medicine has been prescribed for you. Do not pass it on
to others. It may harm them, even if their symptoms are the
same as yours.
• If any of the side effects gets serious, or if you notice any
side effects not listed in this leaflet, please tell your doctor
or pharmacist.
_1.WHAT ZOLMITRIPTAN ORODISPERSIBLE TABLETS _
_ARE AND WHAT THEY ARE USED FOR_
Zolmitriptan Orodispersible Tablets contain zolmitriptan and
belong to a group of medicines called triptans.
ZOLMITRIPTAN ORODISPERSIBLE TABLETS ARE USED TO TREAT
MIGRAINE HEADACHE.
• Migraine symptoms may be caused by the widening of blood
vessels in the head. Zolmitriptan Orodispersible Tablets are
thought to reduce the widening of these blood vessels.
This helps to take away the headache and other symptoms
of a migraine attack, such as feeling or being sick (nausea or
vomiting) and being sensitive to light and sound.
• Zolmitriptan Orodispersible Tablets work only when a
migraine attack has started. They will not stop you from
getting an attack.
_2.BEFORE YOU TAKE ZOLMITRIPTAN ORODISPERSIBLE_
_TABLETS_
DO NOT TAKE ZOLMITRIPTAN ORODISPERSIBLE TABLETS IF:
• you are allergic (hypersensitive) to zolmitriptan or any of
the other ingredients of this medicine (see Section 6: Further
information).
• you have high blood pressure.
• you have ever had heart problems, including a heart attack,
angina (chest pain caused by exercise or effort), Prinzmetal's
angina (chest pain which happens at rest) or have
experienced heart related symptoms such as shortness of
breath or pressure over the chest.
• you have had a stroke or short-lasting symptoms similar to
stroke (transient ischaemic attack or TIA).
• you have severe

Summary of Product characteristics

OBJECT 1
ZOLMITRIPTAN 5 MG ORODISPERSIBLE TABLETS
(ARROW)
Summary of Product Characteristics Updated 14-Nov-2013 | Accord-UK Ltd
1. Name of the medicinal product
Zolmitriptan 5 mg Orodispersible Tablets
2. Qualitative and quantitative composition
Zolmitriptan
Each 5 mg orodispersible tablet contains 5 mg of zolmitriptan.
For a full list of excipients, see 6.1.
3. Pharmaceutical form
Orodispersible tablet
White, round, flat tablets with a diameter of 8.0 mm approximately.
4. Clinical particulars
4.1 Therapeutic indications
Acute treatment of migraine headache with or without aura.
4.2 Posology and method of administration
The recommended dose of Zolmitriptan Orodispersible Tablets to treat a
migraine attack is 2.5 mg. It is
advisable that Zolmitriptan Orodispersible Tablets is taken as early
as possible after the onset of migraine
headache but it is also effective if taken at a later stage.
The tablet need not be taken with liquid; the tablet dissolves on the
tongue and is swallowed with saliva.
This formulation can be used in situations in which liquids are not
available, or to avoid the nausea and
vomiting that may accompany the ingestion of tablets with liquids.
However, a delay in the absorption of
zolmitriptan from Zolmitriptan Orodispersible Tablets can occur which
may delay onset of action.
The blister pack should be peeled open as shown on the foil (tablets
should not be pushed through the
foil). The Zolmitriptan tablet should be placed on the tongue, where
it will dissolve and be swallowed
with the saliva.
If symptoms of migraine should recur within 24 hours, following an
initial response, a second dose may
be taken. If a second dose is required, it should not be taken within
2 hours of the initial dose. If a patient
does not respond to the first dose, it is unlikely that a second dose
will be of benefit in the same attack.
If a patient does not achieve satisfactory relief with 2.5 mg doses,
for subsequent attacks 5mg doses of
Zolmitriptan Orodispersible Tablets could be considered.
The total daily intake